Panic in Australia

SummaryPanic disorder is widespread in Australia, often in combination with other psychiatric conditions such as agoraphobia or major depression. Pharmacotherapy for panic disorder in Australia commenced with benzodiazepines, and later progressed to tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). More recently, treatment has moved towards use of the selective serotonin reuptake inhibitors (SSRIs), which are effective and better tolerated. Paroxetine is the first drug of this class to receive approval for treatment of panic disorder in Australia.

Download Full-text

Review: selective serotonin reuptake inhibitors as effective as tricyclic antidepressants for major depression, and may have fewer adverse effects

Evidence-Based Mental Health ◽

10.1136/ebmh.6.4.117 ◽

2003 ◽

Vol 6 (4) ◽

pp. 117-117 ◽

Cited By ~ 2

Author(s):

A. Cipriani

Keyword(s):

Major Depression ◽

Adverse Effects ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Tricyclic Antidepressants ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin

Download Full-text

Switching Antidepressants vs. Conventional Augmentation Strategies

CNS Spectrums ◽

10.1017/s1092852900003527 ◽

2009 ◽

Vol 14 (S4) ◽

pp. 11-14 ◽

Cited By ~ 5

Author(s):

George I. Papakostas

Keyword(s):

Monoamine Oxidase ◽

Mechanism Of Action ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Tricyclic Antidepressants ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin ◽

Augmentation Strategies ◽

The 1960S ◽

Norepinephrine Reuptake

Antidepressants have been available since the 1950s, when the monoamine oxidase inhibitors were first discovered. Since then, our armamentarium of antidepressants has progressively expanded with the discovery of the tricyclic antidepressants (TCAs) in the 1960s, the selective serotonin reuptake inhibitors (SSRIs) in the 1980s, and, subsequently, the serotonin norepinephrine reuptake inhibitors (SNRIs), and other agents possessing a diverse mechanism of action including buproprion, and mirtazapine.

Download Full-text

A REVIEW OF MEDICINAL PLANTS POSSESSING ANTIDEPRESSANT POTENTIAL

INDIAN DRUGS ◽

10.53879/id.53.06.10436 ◽

2016 ◽

Vol 53 (06) ◽

pp. 5-17

Author(s):

A. K. Dhingra ◽

◽

B. Chopra ◽

R Dass ◽

S. K. Mittal

Keyword(s):

Major Depression ◽

Medicinal Plants ◽

Monoamine Oxidase ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Tricyclic Antidepressants ◽

Antidepressant Activity ◽

Serotonin Reuptake Inhibitors ◽

Full Remission ◽

Dopaminergic Systems

Major depression is a debilitating disorder, predicted to be the second most prevalent human malady by the year 2020. Although a variety of chemical antidepressant remedies like tricyclic antidepressants, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors are available, yet approximately 30% of depressed patients are resistant to the existing drugs and remaining 70% do not achieve full remission. Therefore, a constant urge continues for discovery of newer, better-tolerated and more efficacious treatments of depression, which include search for discovery of medicinal plants with potential antidepressant activity. The present paper discusses anti-depression potential of 70 medicinal plants with emphasis on their pre-clinical and clinical reports. Majority of plants shows antidepressant activity through serotonergic, noradrenergic and dopaminergic systems.

Download Full-text

Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases

The Journal of Maternal-Fetal & Neonatal Medicine ◽

10.3109/14767058.2013.766697 ◽

2013 ◽

Vol 26 (11) ◽

pp. 1066-1068 ◽

Cited By ~ 10

Author(s):

Faruk Uguz

Keyword(s):

Major Depression ◽

Panic Disorder ◽

Pregnant Women ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Low Dose ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin ◽

Severe Nausea

Download Full-text

Antidepressant Treatment of Psychotic Major Depression: Potential Role of the σ Receptor

CNS Spectrums ◽

10.1017/s1092852900022641 ◽

2005 ◽

Vol 10 (4) ◽

pp. 319-323 ◽

Cited By ~ 36

Author(s):

Stephen M. Stahl

Keyword(s):

Major Depression ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Tricyclic Antidepressants ◽

Antidepressant Treatment ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin ◽

Severe Condition ◽

Psychotic Major Depression

AbstractPsychotic major depression is a severe condition that frequently proves difficult-to-treat. The most effective traditional treatments (electroconvulsive therapy and combinations of antipsychotics with tricyclic antidepressants) are associated with significant side effects, and the use of tricyclic antidepressants alone is largely ineffective. Recent evidence has indicated that the selective serotonin reuptake inhibitors, either alone or in combination with antipsychotics, may provide a desirable alternative to traditional treatments. Among selective serotonin reuptake inhibitors, fluvoxamine has been the best studied and, somewhat surprisingly, has proven effective in several studies as a monotherapy without the need to combine with an antipsychotic. It is proposed that the apparent efficacy of fluvoxamine in psychotic major depression may be related to its unique property of high affinity for the σ1receptor, which is thought to play a role in psychosis and in the action of some antipsychotic drugs.

Download Full-text